Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer's Related Pathological Changes in Down Syndrome

Authors

Boris Decourt, Banner Sun Health Research Institute, Sun City AZ, USA.
William Mobley, University of California-San Diego, San Diego CA, USA.
Eric Reiman, Banner Alzheimer's Institute, Phoenix AZ, USA.
Raj Jatin Shah, Banner Sun Health Research Institute, Sun City AZ, USA.
Marwan N. Sabbagh, Banner Sun Health Research Institute, Sun City AZ, USA.Follow

Document Type

Article

Abstract

Down syndrome is one of the most common genetic conditions occurring in one in 700 live births. The trisomy of chromosome 21 causes over-expression of APP which in turn is indicated in the increased production of Aβ associated with AD. This makes DS the most common presenile form of AD exceeding PS1 and PS2 FAD. Since a majority of DS individuals develop dementia, it is important to examine whether DS and sporadic AD share common features, for example, to anticipate shared treatments in the future. Here we explore commonalities and differences for secretases and endosomal pathways in DS and AD.

Publication Date

3-20-2013

Publication Title

Journal of Alzheimer's disease & Parkinsonism

ISSN

2161-0460

Volume

Suppl 7

First Page

002

PubMed ID

24782952

Digital Object Identifier (DOI)

10.4172/2161-0460.S7-002

Recommended Citation

Decourt, Boris; Mobley, William; Reiman, Eric; Shah, Raj Jatin; and Sabbagh, Marwan N., "Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer's Related Pathological Changes in Down Syndrome" (2013). Neurology. 1013.
https://scholar.barrowneuro.org/neurology/1013